SCHEMBL10112436

SCHEMBL10112436

c1ccc(-c2nnc(-c3ccccc3-c3c4ccccc4c(-c4ccccc4-c4nnc(-c5ccccc5)o4)c4cc(N(c5ccccc5)c5ccc(N(c6ccccc6)c6ccccc6)cc5)ccc34)o2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 16/20 0.44
NPC1 O15118 14/20 0.44
SMN1; SMN2 Q16637 11/20 0.44
ALDH1A1 P00352 9/20 0.44
HPGD P15428 9/20 0.44
TSHR P16473 6/20 0.44
KDM4E B2RXH2 7/20 0.43
GAA P10253 1/20 0.43
MAPT P10636 3/20 0.42
NFKB1 P19838 3/20 0.42
NFKB2 Q00653 3/20 0.42
RELA Q04206 3/20 0.42
LMNA P02545 2/20 0.42
CYP1A2 P05177 2/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
RXFP1 Q9HBX9 1/20 0.41
HSD17B10 Q99714 3/20 0.41
TP53 P04637 3/20 0.41
NPSR1 Q6W5P4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10112694 0.89 RAB9A (0.41) RAB9ANPC1SMN1; SMN2ALDH1A1HPGD
SCHEMBL10112429 0.88 NPC1 (0.47) RAB9ANPC1SMN1; SMN2ALDH1A1HPGD
SCHEMBL10112570 0.87 RAB9A (0.40) RAB9ANPC1SMN1; SMN2ALDH1A1HPGD
SCHEMBL10112430 0.86 NPC1 (0.46) RAB9ANPC1SMN1; SMN2ALDH1A1HPGD
SCHEMBL10112437 0.83 RAB9A (0.41) RAB9ANPC1SMN1; SMN2ALDH1A1HPGD
SCHEMBL37086 0.82 ALDH1A1 (0.37) RAB9ANPC1SMN1; SMN2ALDH1A1HPGD
SCHEMBL18561896 0.82 ALDH1A1 (0.37) RAB9ANPC1SMN1; SMN2ALDH1A1HPGD
SCHEMBL175637 0.82 RAB9A (0.56) RAB9ANPC1SMN1; SMN2ALDH1A1HPGD
SCHEMBL17955168 0.81 RAB9A (0.55) RAB9ANPC1SMN1; SMN2ALDH1A1HPGD
SCHEMBL14466543 0.81 RAB9A (0.55) RAB9ANPC1SMN1; SMN2ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8110980-B2 Anthracene derivative, and light emitting element, light emitting device, electronic device using anthracene derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2012-02-07 US disclosed
US-8110980-B2 Anthracene derivative, and light emitting element, light emitting device, electronic device using anthracene derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2012-02-07 US disclosed
US-20100164376-A1 Anthracene Derivative, and Light Emitting Element, Light Emitting Device, Electronic Device Using Anthracene Derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2010-07-01 US disclosed
US-20100164376-A1 Anthracene Derivative, and Light Emitting Element, Light Emitting Device, Electronic Device Using Anthracene Derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2010-07-01 US disclosed
US-7674914-B2 novel anthracene derivative represented by General Formula (1) is provided, which enables the production of a light-emitting element with high luminous efficiency and a long lifetime. A high-performance light-emitting device and electronic device in which the anthracene derivative light emitting diode SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2010-03-09 US disclosed
US-7674914-B2 novel anthracene derivative represented by General Formula (1) is provided, which enables the production of a light-emitting element with high luminous efficiency and a long lifetime. A high-performance light-emitting device and electronic device in which the anthracene derivative light emitting diode SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2010-03-09 US disclosed
US-20080103315-A1 Anthracene Derivative, and Light Emitting Element, Light Emitting Device, Electronic Device Using Anthracene Derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2008-05-01 US disclosed
US-20080103315-A1 Anthracene Derivative, and Light Emitting Element, Light Emitting Device, Electronic Device Using Anthracene Derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2008-05-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080103315-A1 Anthracene Derivative, and Light Emitting Element, Light Emitting Device, Electronic Device Using Anthracene Derivative AMY1A, CYP1A1, CRY1 RAB9A 2483/4885NPC1 3526/4885SMN1; SMN2 2116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.